CITATION REPORT List of articles citing

Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors

DOI: 10.2967/jnumed.120.258772 Journal of Nuclear Medicine, 2021, 62, 1558-1563.

Source: https://exaly.com/paper-pdf/79125073/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
17	Targeted Cancer Therapy: Whatas New in the Field of Neuroendocrine Neoplasms?. <i>Cancers</i> , 2021 , 13,	6.6	6
16	Functioning and nonfunctioning pNENs. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021 , 18, 284-290	1.7	О
15	Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2021 , 11, 687925	5.3	1
14	Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals <i>Cancers</i> , 2022 , 14,	6.6	2
13	Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies <i>Cancers</i> , 2022 , 14,	6.6	2
12	Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives <i>World Journal of Gastrointestinal Surgery</i> , 2022 , 14, 78-106	2.4	
11	New Insights in PRRT: Lessons From 2021 Frontiers in Endocrinology, 2022, 13, 861434	5.7	1
10	Clinical pharmacology of radiotheranostics in oncology <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	2
9	Nicht nur bei NET: Somatostatinrezeptor-gerichtete Theranostik. <i>InFo Hinatologie + Onkologie</i> , 2022 , 25, 17-21	Ο	
8	Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms. <i>World Journal of Gastrointestinal Surgery</i> , 2022 , 14, 397-408	2.4	
7	Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. <i>Cancers</i> , 2022 , 14, 3317	6.6	
6	Visualized radio-clinical biomarker for predicting neoadjuvant chemotherapy response and prognosis from pretreatment oversampled CT images of LAGC patients: A multicenter study.		
5	Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review.		3
4	Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment. 2023, 18, 201-214		0
3	68Ga-DOTATOC PET/CT Imaging of a Muscular Solitary Fibrous Tumor. 2023 , 48, e228-e229		O
2	Imaging Recommendations for Theranostic PET-CT in Oncology.		0
1	Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases. 2023 , 12, 2456		O